Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A highly drug resistant malaria "superbug" from western Cambodia is now present in southern Vietnam, leading to alarming failure rates for dihydroartemisinin (DHA)-piperaquine — Vietnam’s national first-line malaria treatment, leading malaria scientists warn.

Plasmodium falciparum C580Y mutant malaria parasite

The spread of this dominant artemisinin drug resistant P falciparum C580Y mutant malaria parasite lineage across the entire Mekong Sub-region is a serious threat to malaria control and eradication efforts, the scientists say in a letter published today in The Lancet Infectious Diseases.

"A single mutant strain of very drug resistant malaria has now spread from western Cambodia to north-eastern Thailand, southern Laos and into southern Vietnam and caused a large increase in treatment failure of patients with malaria," says letter co-author Oxford Prof. Arjen Dondorp, Head of Malaria and Deputy Head of the Mahidol Oxford Tropical Medicine Research Unit (MORU) in Thailand, Asia.

“This could result in an important increase in malaria transmission in these countries and severely jeopardize their malaria elimination efforts,” said Prof. Dondorp. “We hope this evidence will be used to reemphasize the urgency of malaria elimination in the Mekong sub-region before falciparum malaria becomes close to untreatable.”

The spread of artemisinin resistance in Plasmodium falciparum and the subsequent loss of partner antimalarial drugs in the Greater Mekong sub-region presents one of the greatest threats to the control and elimination of malaria, the letter authors say.

“We are losing a dangerous race. The spread of this malaria “superbug” has caused an alarming rise in treatment failures forcing changes in drug policy and leaving few options for the future,” said said letter co-author and Mahidol and Oxford University Prof Sir Nicholas White. “We need to tackle this public health emergency urgently.”

Michael Chew from Wellcome's Infection and Immunobiology team said: "The spread of this malaria "superbug" strain, resistant to the most effective drug we have, is alarming and has major implications for public health globally. Around 700,000 people a year die from drug-resistant infections, including malaria. If nothing is done, this could increase to millions of people every year by 2050. Efforts to help track resistance to drugs are vital for improving diagnosis, treatment, and control of drug resistant infections."

Similar stories

MORU hepatitis work focusses on preventing mother-to-child transmission, high-at-risk populations, and remote communities

MORU Tropical Health Network researchers in Southeast Asia study various aspects of hepatitis B and C, infections that can lead to chronic liver diseases, and complications like liver cancer or cirrhosis. Researchers at MOCRU work on treatment for hepatitis C, a frequent opportunistic infection in HIV patients. MORU’s Clinical Pharmacology conducts two trials on possible treatments of hepatitis C. Hepatitis B is frequently transmitted from mother to child at birth, and SMRU researchers study mothers’ knowledge and behaviour, as well as prevention.

Incomplete reporting of COVID-19 disease severity criteria compromises meta-analysis

Patients affected by COVID-19 should be treated according to the severity of their disease. However, not all key national or international organisations define severity in the same way. This imprecision in severity assessment compromises the validity of some therapeutic recommendations. Using individual patient data would better guide and improve therapeutic recommendations for COVID-19.

Field evaluation of EasyScan GO: a digital malaria microscopy device

Microscopic examination of Giemsa-stained blood films is key to quantifying and detecting malaria parasites but there can be difficulties in ensuring both a high-quality manual reading and inter-reader reliability. The EasyScan GO was developed as a potential solution to this, a microscopy device using machine-learning-based image analysis for automated parasite detection and quantification.

Enhanced vaccination against Japanese encephalitis virus could reduce encephalitis prevalence by one third in SE Asia

Encephalitis is a worldwide public health issue, with a substantially high burden among children in Southeast Asia. A large study of the causes of childhood encephalitis in SE Asia suggests that enhanced and effective vaccination against the Japanese encephalitis virus alone could reduce encephalitis prevalence by one third.

Congratulations to Professor Sir David Warrell, appointed Knight Commander of the Order of St Michael and St George!

David Warrell, MORU founding director, has been appointed by the Queen ‘Knight Commander of the Order of St Michael and St George for services to global Health Research and Clinical Practice’. Please join us in congratulating Sir David on receiving this richly deserved high honour!

Laos’ first Pint of Science: warty newts, COVID, AI for Instagram, and more!

Organised by a grass-root community of thousands of scientists across the world, Pint of Science 2022 allows researchers in 25 countries and over 800 cities to share their latest findings with lay folk in interesting, informal settings. Lao PDR joined the global Pint of Science family on Monday 9 May, when the first-ever Pint of Science Laos kicked off!